Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 18;13(3):513-517.
doi: 10.18240/ijo.2020.03.22. eCollection 2020.

Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome

Ying-Ying Yu  1   2   3   4 , Xiao-Xin Li  1   2   3   4 , Jian-Hong Liang  1   2   3   4
Affiliations

Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome

Ying-Ying Yu et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the efficacy of ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma (DCH) in Sturge-Weber syndrome (SWS).

Methods: A total of 8 patients with DCH in SWS managed with plaque brachytherapy were retrospectively included. Patients were treated with ruthenium-106 plaque therapy (median apex dose: 83 Gy) at the thickest tumor region. On follow-up, we recorded the tumor thickness, the best-corrected visual acuity (BCVA), subretinal fluid (SRF) status, and complications following treatment.

Results: At a median follow-up of 43mo, tumor regression was observed in all cases, with a complete resolution of SRF and reduction in tumor-thickness. No radiation complications were recorded during the follow up time.

Conclusion: Ruthenium-106 plaque therapy to the thickest portion of the tumor seems to be a useful treatment in patients with DCH in SWS.

Keywords: Sturge-Weber syndrome; diffuse choroidal hemangioma; plaque brachytherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Follow-up of a 9-year old boy with DCH during SWS
A: Fundus images demonstrating DCH with extensive exudative retinal detachment at initial presentation; B: 18mo post-brachytherapy, post-treatment fundus images showing tumor regression and a lack of SRF; C: Fluorescein angiogram highlighting regions of degeneration in the retinal pigment epithelium and DCH leakage; D: Fluorescein angiogram 23mo after plaque radiotherapy shows hyperfluorescence in the treatment area; E: B-scan ultrasonography showing the elevated nodular component of a DCH with extensive exudative retinal detachment and the thickest portion at the temporal side before treatment; F: B-scan ultrasonography illustrating regression of the nodular component 23mo after treatment; G: OCT of the right macula imaged at 11mo post-treatment showing regular foveal contours and SRF resolution.
See this image and copyright information in PMC

References

    1. Gass JDM. Differential diagnosis of intraocular tumors: a stereoscopic presentation. St Louis, MO: Mosby; 1974. pp. 113–138.
    1. Zografos L, Bercher L, Chamot L, Gailloud C, Raimondi S, Egger E. Cobalt-60 treatment of choroidal hemangiomas. Am J Ophthalmol. 1996;121(2):190–199. - PubMed
    1. Murthy R, Hanovaz SG, Naik M, Gopi S, Reddy VA. Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal haemangioma in Sturge-Weber syndrome. Indian J Ophthalmol. 2005;53(4):274–275. - PubMed
    1. Kubicka-Trząska A, Kobylarz J, Romanowska-Dixon B. Ruthenium-106 plaque therapy for diffuse choroidal hemangioma in sturge-weber syndrome. Case Rep Ophthalmol Med. 2011;2011:785686. - PMC - PubMed
    1. Arepalli S, Shields CL, Kaliki S, Emrich J, Komarnicky L, Shields JA. Diffuse choroidal hemangioma management with plaque radiotherapy in 5 cases. Ophthalmology. 2013;120(11):2358–2359. 2359.e1–2. - PubMed

LinkOut - more resources